Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study. - Laurent Mortier; Lisa Villabona; Ben Lawrence; Ana Arance; Marcus O. Butler; M. Beylot?Barry; Philippe Saïag; Mahtab Samimi; Paolo A. Ascierto; Francesca Spada; Michel De Pontville; Michele Maio; et al. (AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024)